Ewing sarcoma

CancerVax Announces Promising New Drug to Treat a Deadly Children’s Cancer

Retrieved on: 
Martedì, Aprile 16, 2024
UCLA, FDA, Radiation, Cancer, CancerVax, Research, IND, Oncology, Barbara, Weapon, Ewing sarcoma, Protocol, Neoplasm, Immune system, Investigational New Drug, Vaccine

Ewing sarcoma is a rare and deadly bone and soft tissue cancer that primarily affects children and young adults.

Key Points: 
  • Ewing sarcoma is a rare and deadly bone and soft tissue cancer that primarily affects children and young adults.
  • The research program, funded by CancerVax, is led by a world class team of cancer researchers and oncologists who run the Ewing Sarcoma Program at the UCLA Jonsson Comprehensive Cancer Center.
  • This new type of cancer drug uses the body’s own immune system to fight cancer.
  • We believe this is a better way to treat cancer rather than the old methods of chemotherapy, radiation, and surgery.

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Venerdì, Marzo 22, 2024
Research, Topotecan, TC, LSD1, Survival, Bone marrow, Progression-free survival, DCR, Patient, Acquisition, Deuterium, NHL, IND, Myelodysplastic syndrome, Non-Hodgkin lymphoma, Clinical trial, Azacitidine, Chronic myelomonocytic leukemia, Probability, Cyclophosphamide, FDA, MD Anderson Cancer Center, Ewing sarcoma, Consultant, Food, Pharmaceutical industry

HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today reported financial results for the three and 12 months ended December 31, 2023 and provided a business update.

Key Points: 
  • Cash and cash equivalents were $5.9 million as of December 31, 2023, compared with $12.1 million as of December 31, 2022.
  • In August 2023 Salarius announced a comprehensive review of strategic alternatives focused on maximizing shareholder value.
  • Research and development expenses were $0.06 million for the fourth quarter of 2023, compared with $4.7 million for the fourth quarter of 2022, reflecting the above-mentioned cost-savings plan.
  • Net cash used for operating activities during the fourth quarter of 2023 was $1.5 million, compared with $4.7 million during the same quarter in 2022, reflecting the above-mentioned cost-savings plan.

Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Retrieved on: 
Giovedì, Febbraio 22, 2024
Ewing sarcoma, Cyclophosphamide, Canaccord Genuity, Chairperson, Patient, Clinical trial, MD Anderson Cancer Center, TC, Cancer, Pharmaceutical industry

HOUSTON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, today announced that its Board of Directors is implementing a series of additional cost-savings measures designed to extend Salarius’ expected cash runway into the first half of 2025. These measures will allow Salarius to support the generation of additional clinical data for seclidemstat in the ongoing MD Anderson Cancer Center (MDACC) investigator-initiated Phase 1/2 clinical trial in hematologic cancers and Salarius’ Phase 1/2 trial in Ewing sarcoma.

Key Points: 
  • These measures will allow Salarius to support the generation of additional clinical data for seclidemstat in the ongoing MD Anderson Cancer Center (MDACC) investigator-initiated Phase 1/2 clinical trial in hematologic cancers and Salarius’ Phase 1/2 trial in Ewing sarcoma.
  • “With these additional expense reductions, we are able to extend our cash runway to allow for the generation of additional clinical data in both seclidemstat clinical trials.
  • “By further reducing expenses, we are able to support the ongoing clinical development of seclidemstat into the first half of 2025.
  • We look forward to reviewing the updated clinical data from both trials later this year and to sharing those data with prospective strategic partners and other interested parties.”

UT Health San Antonio secures $16.4 million from CPRIT over six months, adding transformative expertise, bolstering cancer research

Retrieved on: 
Venerdì, Marzo 8, 2024
Doctor of Philosophy, Education, MD, Drug development, DNA repair, National Cancer Institute, Breast, University, RNA, Research institute, Ovarian cancer, Cell Systems, Health, Genetics, Anatomy, Biochemistry, Bangladesh Technical Education Board, Algorithm, Adolescence, Nursing, Neoplasm, Kitagawa, Faculty, Dentistry, HPV, Child, DNA, Chromatin, Therapy, SAN, National Institutes of Health, Mentorship, Chromosome instability, Doctor of Pharmacy, Structural biology, Vaccination, Cancer Research Institute, Molecular medicine, News, Laboratory, Research, University of Texas System, Cedars-Sinai Medical Center, Survivor, BRCA2, Cell, Howard Hughes Medical Institute, School, Cancer prevention, Luan, BRCA1, Patient, Teaching, Ewing sarcoma, Cancer, Public, Vaccine

SAN ANTONIO, March 7, 2024 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) (https://uthscsa.edu/) has secured approximately $16.4 million in funding from the Cancer Prevention and Research Institute of Texas (https://www.cprit.state.tx.us/about-us) the past six months, attracting three top cancer researchers and advancing child and adolescent cancer research.

Key Points: 
  • SAN ANTONIO, March 7, 2024 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) ( https://uthscsa.edu/ ) has secured approximately $16.4 million in funding from the Cancer Prevention and Research Institute of Texas ( https://www.cprit.state.tx.us/about-us ) the past six months, attracting three top cancer researchers and advancing child and adolescent cancer research.
  • The Mays Cancer Center at UT Health San Antonio ( https://cancer.uthscsa.edu/ ) is one of only four National Cancer Institute-designated Cancer Centers in Texas.
  • The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas.
  • The Greehey Children's Cancer Research Institute ( https://cancer.uthscsa.edu/gccri ) is one of only two institutes in the United States dedicated solely to pediatric cancer research.

International Team Led by CHOP Cancer Expert Receives Multimillion Dollar Grant for Childhood Cancer Research from Cancer Grand Challenges

Retrieved on: 
Mercoledì, Marzo 6, 2024
Survivor, Oncogene, Ewing sarcoma, Doctor of Philosophy, Neoplasm, Cancer Research UK, Hospital, Neuroblastoma, Child, National Cancer Institute, Medulloblastoma, University, Therapy, KiKa, Protein, CHOP, Survival, Pediatrics, Team, Fibrolamellar hepatocellular carcinoma, Rhabdomyosarcoma, Partnership, Pharmaceutical industry

PHILADELPHIA, March 6, 2024 /PRNewswire/ -- An interdisciplinary, global team of scientists led by Yael Mossé, MD, Professor of Pediatrics in the Cancer Center at Children's Hospital of Philadelphia (CHOP), has been selected as one of five research teams from all over the world to receive funds from Cancer Grand Challenges, a funding initiative co-founded by the National Cancer Institute and Cancer Research UK. Mossé's international team will receive up to $25 million to develop transformative new therapies for previously undruggable forms of childhood cancer.

Key Points: 
  • Mossé's international team will receive up to $25 million to develop transformative new therapies for previously undruggable forms of childhood cancer.
  • Last year, 176 global teams submitted bold ideas for tackling some of the most pressing challenges in cancer research and care.
  • The National Cancer Institute and Cancer Research UK, the world's leading funders of cancer research, co-founded and launched the Cancer Grand Challenges initiative in 2020.
  • In addition to the Team KOODAC3 award, Team MATCHMAKERS, which includes Dr. Nikolaos G. Sgourakis from CHOP, also received a Cancer Grand Challenges award of up to $25 million.

The Washington, D.C. Auto Show, the Washington Area Hyundai Dealers and Hyundai Hope on Wheels Team up to Support Georgetown Lombardi and Children’s National Hospital Through “Hyundai Hands On Hope” Contest

Retrieved on: 
Mercoledì, Gennaio 17, 2024
Research, Cancer, NCI, Young adult, National Cancer Institute, Walter, Washington Convention Center, Diagnosis, Adolescence, Hope, Hackensack Meridian Health, L Street Bridge, Hyundai Motor America, Washington Auto Show, Georgetown University Medical Center, MedStar Health, Health, Hyundai, Child, Hospital, Human, Ewing sarcoma, Contest, Partnership, News, Nursing, Clinical trial, Automotive industry

Drawing inspiration from Hyundai Hope on Wheels, the new contest was named “Hyundai Hands On Hope.”

Key Points: 
  • Drawing inspiration from Hyundai Hope on Wheels, the new contest was named “Hyundai Hands On Hope.”
    Six contestants will compete for a brand-new 2024 Hyundai IONIQ6 over the 44-hour contest period.
  • “Every 36 minutes a child is diagnosed with pediatric cancer” shared Kevin Reilly, President of The Washington Area Hyundai Dealers, and Vice Chair of Hyundai Hope on Wheels.
  • In 2023, Hyundai Hope on Wheels celebrated its 25th Anniversary since inception, donating over $225 million in pediatric cancer research grants.
  • A part of Georgetown University Medical Center, Georgetown Lombardi is the only comprehensive cancer center in the Washington, D.C., area.

Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates

Retrieved on: 
Giovedì, Gennaio 4, 2024
Actinium, Food, Șaeș, Tat, SRC, IND, Arm, TAT, Antibody, PSMA, DLT, Radiation, FDA, Spacecraft, Literature, Infrared spectroscopy correlation table, Standard of care, Cohort, Thrombocytopenia, GMP, Pancreatic cancer, Prostate, Toxicity, Interim, Investment, Actinium-225, Patient, Safety, Ewing sarcoma, OS, PFS, PSA, Pharmaceutical industry

In February 2023, Fusion acquired an IND for the ongoing Phase 2 clinical trial (the TATCIST trial) evaluating FPI-2265 (225Ac-PSMA I&T).

Key Points: 
  • In February 2023, Fusion acquired an IND for the ongoing Phase 2 clinical trial (the TATCIST trial) evaluating FPI-2265 (225Ac-PSMA I&T).
  • Fusion announced today encouraging early findings from Cohort 2 in the ongoing FPI-1434 Phase 1 clinical trial.
  • Fusion reported today that it has completed validation of its state-of-the-art good manufacturing practice (GMP) manufacturing facility and produced the first clinical dose of a TAT.
  • We built Fusion on a foundation of end-to-end manufacturing expertise, including experience with global radiopharmaceutical logistics and distribution.

Meet the St. Baldrick's Foundation 2024 Ambassadors

Retrieved on: 
Mercoledì, Gennaio 3, 2024
Immunosuppression, MRI, Neoplasm, Swimming, Acute lymphoblastic leukemia, APL, Research, St. Baldrick's Foundation, Ambassador, Jack Sparrow, Clinical trial, Cancer, Juju, Acute promyelocytic leukemia, LOS, Dance, Acute myeloid leukemia, Diagnosis, ALL, Ewing sarcoma, AML, San Diego State University, Radiation, Child

LOS ANGELES, Jan. 3, 2024 /PRNewswire/ -- The St. Baldrick's Foundation, the largest charity funder of childhood cancer research grants, is proud to introduce its 2024 Ambassadors who along with their families, will share their unique journey and experiences associated with childhood cancer.

Key Points: 
  • The St. Baldrick's Foundation introduces its 2024 Ambassadors to raise awareness about the need to fund childhood cancer research to find cures and better treatments.
  • LOS ANGELES, Jan. 3, 2024 /PRNewswire/ -- The St. Baldrick's Foundation , the largest charity funder of childhood cancer research grants , is proud to introduce its 2024 Ambassadors who along with their families, will share their unique journey and experiences associated with childhood cancer.
  • Now 12 years in remission, Scott is enjoying the 9th grade and is a passionate advocate for childhood cancer research.
  • Continue following the St. Baldrick's 2024 Ambassadors' heroic stories on the St. Baldrick's blog and social media channels: Facebook , X , Instagram , YouTube , Tik Tok and LinkedIn .

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Retrieved on: 
Mercoledì, Gennaio 3, 2024
DCR, LSD1, SUSAR, Database, Canaccord Genuity, Food, Survival, Learning, Cyclophosphamide, Chronic myelomonocytic leukemia, Probability, Bone marrow, FDA, TC, Progression-free survival, Myelodysplastic syndrome, CMML, MD, MDS, Clinical trial, Monroe Dunaway Anderson, University, Azacitidine, Effectiveness, MD Anderson Cancer Center, Sarcoma, Patient, Ewing sarcoma, Pharmaceutical industry

While these efforts are ongoing, the Company continues to support the continuation of its clinical programs, as appropriate.

Key Points: 
  • While these efforts are ongoing, the Company continues to support the continuation of its clinical programs, as appropriate.
  • In October 2022, the FDA placed the MDACC investigator-initiated trial under a partial clinical hold following a suspected unexpected serious adverse reaction (SUSAR) in the FET-rearranged arm of Salarius’ Phase 1/2 trial with seclidemstat in sarcomas.
  • In addition to the MDACC investigator-initiated clinical trial, seclidemstat has been studied in a company-sponsored Phase 1/2 clinical trial evaluating its use in combination with TC for the treatment of relapsed/refractory Ewing sarcoma.
  • The Company-sponsored Ewing sarcoma clinical trial focuses on seclidemstat in combination with TC as a treatment for relapsed and refractory Ewing sarcoma.

NIQ Catalyzes Growth with Strategic Leadership Appointment to Drive Innovation in Consumer Panel Services

Retrieved on: 
Martedì, Dicembre 19, 2023
Food, Beverage, Fashion, Retail, Convenience Store, Supply Chain Management, Online Retail, Electronic Commerce, Discount, Variety, Data Management, Professional Services, Department Stores, Technology, Data Analytics, Office Products, Restaurant, Bar, Other Retail, Supermarket, Specialty, CPS, FMCG, Growth, Investment, Ewing sarcoma, CPG, Sales

NIQ, a pioneering force in consumer and market intelligence, is proud to announce the appointment of Kris Ewing as the Global President of Consumer Panel Services (CPS) to accelerate growth, foster innovation, and deliver client-centric solutions.

Key Points: 
  • NIQ, a pioneering force in consumer and market intelligence, is proud to announce the appointment of Kris Ewing as the Global President of Consumer Panel Services (CPS) to accelerate growth, foster innovation, and deliver client-centric solutions.
  • Ewing's elevation to the position of Global President of Consumer Panel Services is a testament to NIQ's commitment to elevating data-driven insights to unprecedented heights.
  • "I am incredibly excited about the opportunity to lead in this dynamic landscape,” said Kris Ewing, Global President of Consumer Panel Services at NIQ.
  • NIQ is strategically prioritizing the advancement of Consumer Panel Services across the organization, initiating a series of key actions:
    Fostering greater clarity for clients through the connection of Retail Measurement Services and Consumer Panel Services through dynamic, integrated views on NIQ Discover (launching in 2024).